Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats |
| |
Authors: | Lei Qi Tian Lv Yusheng Cheng Min Yu Honghao Han Hui Kong Weiping Xie Hong Wang Yihua Zhang Zhangjian Huang |
| |
Institution: | 1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, PR China;2. The Affiliated Hospital of Nantong University, 20 West Temple Road, Nantong, Jiangsu 226001, PR China;3. State Key Laboratory of Natural Medicines, Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, PR China |
| |
Abstract: | Given the therapeutic efficacy of fasudil hydrochloride (F) and dichloroacetate (DCA) on pulmonary arterial hypertension (PAH), a new salt fasudil dichloroacetate (FDCA) was designed, synthesized and biologically evaluated. FDCA exhibited comparable ROCK II inhibitory activity relative to fasudil hydrochloride, and suppressed the expression of TNF-α and IL-6 in both PDGF-BB and hypoxia-treated pulmonary arterial smooth muscle cells (PASMCs) and endothelial cells (PAECs). Significantly, FDCA lowered mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP), and decreased right ventricular hypertrophy (RVH) in monocrotaline (MCT)-induced PAH rats. Meanwhile, FDCA remarkably decreased pulmonary artery medial thickness (PAMT) and hyperplasia, restoring the elasticity of elastic fiber, reduced cardiac hypertrophy, and attenuated fibrosis of heart and lung. Collectively, FDCA exhibited triple activities of pulmonary vasodilation, vascular remodeling inhibition and RVH inhibition, suggesting that it may be a promising agent for PAH intervention. |
| |
Keywords: | Corresponding authors Pulmonary arterial hypertension ROCK inhibitors Pyruvate dehydrogenase kinase inhibitors Vascular remodeling Right ventricular hypertrophy |
本文献已被 ScienceDirect 等数据库收录! |
|